In a meta-analysis that examined the activity of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors, which have efficacy in specific patient populations with tumors containing BRCA1/2 mutations, 24 of 43 patients with tumors containing somatic BRCA mutations treated with PARP inhibitors had a response to therapy across 8 trials.34 Patient 10 was found to have a mutation in ERBB2 (.234G>T p.Q78H MV; VAF = 28.2%) in ctDNA that was not previously present in tumor tissue. This evidence concerns the gene ERBB2 and neoplasm.